https://emerginggrowth.com/cytodyn-otcqb-cydy-reports-early-results-from-first-patient-in-its-phase-1b-2-ccr5-metastatic-triple-negative-breast-cancer-trial/
CytoDyn (OTCQB: CYDY) Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial